Literature DB >> 11814417

MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats.

Nadine Jonkers1, Sophie Sarre, Guy Ebinger, Yvette Michotte.   

Abstract

In vivo microdialysis in freely moving rats was used to investigate the influence of the indirect dopamine receptor agonist levodopa (L-DOPA), alone and combined with the N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine (MK801), on extracellular glutamate levels in the striatum of intact and 6-hydroxydopamine-lesioned rats. L-DOPA (25 mg/kg i.p. after benserazide 10 mg/kg i.p.) increased extracellular glutamate levels in the striatum of both intact and dopamine-depleted rats. A prior injection of MK801 (0.1 and 1.0 mg/kg i.p.) did not alter the L-DOPA-induced glutamate release in the striatum of intact rats. In contrast, the L-DOPA-induced increase in glutamate in the striatum of 6-hydroxydopamine-lesioned rats was suppressed by MK801 (0.1 mg/kg i.p.). The data presented here suggest that NMDA receptors do not play a role in the L-DOPA-induced increase in striatal glutamate in intact rats but are involved in the glutamate release in the dopamine-depleted striatum. The suppression of this increase by prior administration of MK801 could represent a neuroprotective effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11814417     DOI: 10.1016/s0006-8993(01)03147-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  17 in total

1.  Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.

Authors:  Corinne Y Ostock; Kristin B Dupre; Karen L Eskow Jaunarajs; Hannah Walters; Jessica George; David Krolewski; Paul D Walker; Christopher Bishop
Journal:  Neuropharmacology       Date:  2011-05-27       Impact factor: 5.250

2.  Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.

Authors:  Tanya Chotibut; Samantha Meadows; Ella A Kasanga; Tamara McInnis; Mark A Cantu; Christopher Bishop; Michael F Salvatore
Journal:  Mov Disord       Date:  2017-06-20       Impact factor: 10.338

Review 3.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

4.  Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.

Authors:  Kristin B Dupre; Corinne Y Ostock; Karen L Eskow Jaunarajs; Thomas Button; Lisa M Savage; William Wolf; Christopher Bishop
Journal:  Exp Neurol       Date:  2011-02-22       Impact factor: 5.330

5.  In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.

Authors:  Altaf S Darvesh; Richard T Carroll; Werner J Geldenhuys; Gary A Gudelsky; Jochen Klein; Charles K Meshul; Cornelis J Van der Schyf
Journal:  Expert Opin Drug Discov       Date:  2011-02       Impact factor: 6.098

6.  Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model.

Authors:  Andrew J Flores; Mitchell J Bartlett; Lisa Y So; Nicholas D Laude; Kate L Parent; Michael L Heien; Scott J Sherman; Torsten Falk
Journal:  Neurosci Lett       Date:  2014-02-11       Impact factor: 3.046

Review 7.  The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review.

Authors:  Fernando Caravaggio; Shinichiro Nakajima; Eric Plitman; Philip Gerretsen; Jun Ku Chung; Yusuke Iwata; Ariel Graff-Guerrero
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-09-01       Impact factor: 5.067

8.  Apomorphine-induced differences in cortical and striatal EEG and their glutamatergic mediation in 6-hydroxydopamine-treated rats.

Authors:  Vasily Vorobyov; Frank Sengpiel
Journal:  Exp Brain Res       Date:  2008-08-06       Impact factor: 1.972

9.  Association of protein phosphatase 1 gamma 1 with spinophilin suppresses phosphatase activity in a Parkinson disease model.

Authors:  Abigail M Brown; Anthony J Baucum; Martha A Bass; Roger J Colbran
Journal:  J Biol Chem       Date:  2008-03-26       Impact factor: 5.157

10.  Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease.

Authors:  Marcus C Ferguson; Tultul Nayyar; Twum A Ansah
Journal:  Neurochem Int       Date:  2014-04-04       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.